Hospital Mater Dei SA

As of June 30, 2026, Hospital Mater Dei SA carries a market capitalization of 1.60B, placing it among publicly traded companies globally. Its enterprise value stands at 3.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hospital Mater Dei SA's next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Hospital Mater Dei SA has 330.93M shares outstanding.

As of June 30, 2026, Hospital Mater Dei SA trades at a trailing price-to-earnings ratio of 11.34. The price-to-sales ratio is 0.69, and the price-to-book ratio stands at 1.07.

As of June 30, 2026, Hospital Mater Dei SA trades at an EV/EBITDA multiple of 6.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.95 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Hospital Mater Dei SA trades at an EV/FCF ratio of 8.98, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.16B versus a market cap of 1.60B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hospital Mater Dei SA maintains a current ratio of 2.87, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 143.84, indicating elevated leverage, while an interest coverage ratio of 1.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hospital Mater Dei SA posted a return on equity (ROE) of 9.63, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.17 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.81, useful for judging operating efficiency across full business cycles. The company generates approximately 630,609.46 in revenue per employee across its workforce of 3,677.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 25.03 indicates how many times Hospital Mater Dei SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hospital Mater Dei SA recorded 70.86M in income tax expense. That works out to an effective tax rate of 33.26, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 213.07M, leaving 141.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Hospital Mater Dei SA's stock has gained approximately 50.36% over the past 52 weeks. The 50-day moving average sits at 5.33, while the 200-day moving average is 5.35.

Over the twelve months ended June 30, 2026, Hospital Mater Dei SA generated 2.32B in revenue and converted that into 141.80M in net income, yielding earnings per share of 0.43. EBITDA reached 511.91M, while operating income came in at 398.09M.

As of June 30, 2026, Hospital Mater Dei SA holds 627.83M in cash and equivalents against 2.17B in total debt, resulting in a net debt position of 764.98M. Total book value stands at 1.49B, with working capital of 1.02B providing operational flexibility.

Hospital Mater Dei SA produced 250.02M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -79.69M in capital expenditures, free cash flow totaled 170.33M - equivalent to 0.51 per share.

Over the twelve months ended June 30, 2026, Hospital Mater Dei SA posted a gross margin of 30.34, reflecting its pricing power and cost economics. The operating margin of 17.17 and net profit margin of 6.12 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hospital Mater Dei SA paid dividends of 0.12 per share. The dividend payout ratio of 27.69 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.60, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 14.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hospital Mater Dei SA shareholders.

As of June 30, 2026, Hospital Mater Dei SA has an Altman Z-Score of 1.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.